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Abstract
Background: MicroRNA-138 (miR-138) has been proven to be a tumor suppressor gene in various types of tumors.
However, the expression and the role of miR-138 in human osteosarcoma are still poorly understood. We
investigated the function and the underlying mechanism of miR-138 in osteosarcoma.
Methods: The expression of miR-138 in human osteosarcoma tissues and cell lines was detected by real-time PCR
analysis. The gain-of-function and loss-of-function experiments were performed on osteosarcoma cell lines to
investigate the effects of miR-138 on osteosarcoma progression, and to determine whether differentiated
embryonic chondrocyte gene 2 (DEC2) mediates these effects. Cell proliferation, apoptosis and invasion were
assessed by MTT, flow cytometry and transwell-matrigel assays. Dual-luciferase reporter assay was used to identify
whether DEC2 is a direct target of miR-138.
Results: MiR-138 was significantly downregulated in human osteosarcoma tissues and cell lines. Moreover, miR-138
expression was significantly lower in metastatic osteosarcoma tissues than that in non-metastatic tissues. The
in vitro gain-of-function and loss-of-function experiments demonstrated that miR-138 inhibited cell proliferation
and invasion, and promoted cell apoptosis of human osteosarcoma cells. DEC2 was verified as a direct target of
miR-138, and DEC2 could reverse the inhibitory effect of miR-138 on osteosarcoma progression.
Conclusions: These findings suggested that miR-138 acts as a tumor suppressor in osteosarcoma.miR-138 inhibited
cell proliferation and invasion, as well as promoted cell apoptosis of human osteosarcoma cells, at least partially, by
inhibiting the expression of DEC2. MiR-138/DEC2 may be a novel therapeutic target in osteosarcoma.
Keywords: MicroRNA-138, Osteosarcoma, Differentiated embryonic chondrocyte gene 2, Proliferation, Apoptosis,
Invasion
Background
Osteosarcoma is the most common primary malignant
bone tumor in children and young adults, comprising
2.4 % of all malignancies in pediatric patients, and about
20 % of all primary bone tumors [1]. Osteosarcoma is
highly aggressive, and the 5-year event-free survival rate
for patients with metastatic osteosarcoma is only 14 % [2].
Therefore, elucidating the molecular mechanisms for
osteosarcoma metastasis and exploring molecular markers
to predict tumor aggressiveness are urgently needed.
MicroRNAs (miRNAs or miRs) are small non-coding
RNAs that control cellular function by negatively modu-
lating gene expression at either post-transcriptional or
translational levels [3–5]. In recent years, the role of
miRNAs in the pathogenesis of cancers has been exten-
sively studied [6–9]. The deregulation and aberrant ex-
pression of miRNAs is well-recognized to contribute to
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the development of osteosarcoma [10, 11]. MiR-138 is a
frequently downregulated miRNA in various types of tu-
mors, including colorectal cancer, head and neck squa-
mous cell carcinoma (HNSCC), cholangiocarcinoma,
and lung cancer [12–16]. Several studies have indicated
that downregulation of miR-138 promotes the progres-
sion of tumorigenesis [12, 14, 17–19]. Poos et al. suggest
that miR-138 is related to osteosarcoma cell proliferation
[20]. However, the expression of miR-138 and its role in
human osteosarcoma are still poorly understood.
Differentiated embryonic chondrocyte gene 2 (DEC2)
is a basic helix-loop-helix transcription factor which has
been suggested to play key roles in hypoxia response,
cellular proliferation, cell cycle and circadian regulation,
and carcinogenesis [21–27].
DEC2 has been implicated to act as a tumor suppres-
sor in breast, endometrial, pancreatic and oral cancers
[21, 28, 29]. In contrast to these types of cancers, a study
by Hu et al. indicated that DEC2 may contribute to the
development and progression of osteosarcoma [30].
In the present study, we investigated the expression and
biological function of miR-138 in osteosarcoma. We found
miR-138 expression was downregulated in human osteo-
sarcoma tissues and cell lines. We provided the in vitro
evidence that miR-138 inhibits osteosarcoma cell prolifer-
ation and invasion, and promotes osteosarcoma cell apop-
tosis. Moreover, we demonstrated that DEC2 was a direct
target of miR-138. This study provides new insights into
the pathogenesis of osteosarcoma, and contributes to de-
veloping novel therapeutic strategies for osteosarcoma.
Methods
Patients and tissue samples
This study was approved by the Ethics Committee of
The People ’s Hospital of Dongying City of Shandong
Province. All the patients (or patients’ parents on behalf
of the children) signed an informed consent form prior
to study enrollment. 65 osteosarcoma specimens and the
adjacent normal bone tissues (located > 3 cm away from
the tumor) were obtained from 65 osteosarcoma patients
who underwent surgery at the The People ’s Hospital of
Dongying City of Shandong Province. The clinical char-
acteristics of these patients were shown in Table 1. Fresh
tissues were stored in liquid nitrogen before RNA
extraction.
Cell culture and transfection
The human osteosarcoma cell lines (including MG-
63,U2OS,Saos-2 and SJSA-1), the normal bone cell line
hFOB, and HEK293 cell line were purchased from the
American Type Culture Collection (Manassas,VA, USA).
These cell lines were cultured in Dulbecco’s modified Eagle
medium (DMEM; Gibco, Invitrogen Life Technologies,
Carlsbad, CA, USA) supplemented with 10 % fetal bovine
serum (FBS). Cells were incubated at 37 °C in 5 % CO2 hu-
midity, and were passaged every 2–3 days. MiR-138 mimic
(40 nM), miR-138 inhibitor (40 nM), DEC2-pcDNA3.1
(100 ng), DEC2 siRNA (100 ng) and the negative controls,
including miR-Control (40 nM), pcDNA3.1 vector
(100 ng), siRNA-Contrl (100 ng) were all purchased from
GenePharma (Shanghai, China), and were transfected using
Lipofectamine 2000 (Invitrogen Life Technologies), accord-
ing to the manufacturer’s instructions. About 48 h after
transfection, the transfection efficiency was assessed. The
cells could be used for subsequent analysis when the trans-
fection efficiency was above 80 %.
Real-time quantitative reverse transcription PCR
The miRNAs were isolated from osteosarcoma tissues or
cell lines using a RNeasy/miRNeasy Mini kit (Qiagen,
Limburg, The Netherlands) according to the manufac-
turer’s instructions. Total RNA was isolated using Trizol
reagent (Invitrogen). The cDNAs were synthesized using
a RevertAid™ First Strand cDNA Synthesis kit (Fermen-
tas, Vilnius, Lithuania), and real-time quantitative PCR
was carried out using the SYBR-Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) on a 7900
Real-Time PCR System (Applied Biosystems). Primers
used in this study were: miR-138, 5′-agctggtgttgtgaat-
caggccg-3′(forward), 5′-tggtgtcgtggagtcg-3′(reverse); U6,
5′-ctcgcttcggcagcaca-3′(forward), 5′-aacgcttcacgaatttgc
gt-3′(reverse); DEC2, 5′-gcctaccgtcccacagatta-3′ (for-
ward) and 5′-tgtcgtctcgtttcatgctc-3′ (reverse); GAPDH,
5′-cgaccactttgtcaagctca-3′ (forward) and 5′-aggggtcta-
catggcaactg-3′ (reverse). miR-138 mRNA expression was
normalized to U6 internal control, and DEC2 mRNA ex-
pression was normalized to GAPDH internal control.
Table 1 Clinical characteristics of patients with osteosarcoma
Parameter Cases (%)
Age (years)
≤ 15 24 (36.9)
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Western blot analysis
Total protein extracts were prepared using RIPA buffer
with protease inhibitor Cocktail (Pierce, Rockford, IL,
USA). Protein concentrations were examined using the
BCA Protein Assay Kit (Pierce). Total proteins (20 μg)
were separated on 10 % SDS PAGE and then transferred
onto polyvinylidene fluoride membranes (Millipore,
Billerica, MA, USA). After blocking with 5 % non-fat milk
at 4 °C overnight, the membranes were incubated with
primary antibodies against DEC2 (1:1000, mouse mono-
clonal anti-DEC2, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) or GAPDH (1:5000, mouse monoclonal anti-
GAPDH, Abcam, Cambridge, MA, USA) at 4 °C over-
night, followed by incubation with the secondary antibody
(1:5000, rabbit anti-mouse IgG-HRP, Santa Cruz Biotech-
nology) for 2 h at room temperature. Protein bands were
developed using the ECL western blotting kit (Pierce), and
the band intensity was quantified using Image J software
(National Institutes of Health, Bethesda, MD, USA).
Dual-luciferase reporter assay
The DEC2 3′-untranslated region (3′UTR) containing
the wild type or mutated miR-138 binding sequences
were synthesized by Genescript (Nanjing, Jiangsu,
China), and were cloned into the pmirGLO luciferase re-
porter vector (Promega, Madison, WI, USA). HEK293
cells were transfected with the wild type/mutant DEC2
luciferase reporter vector and miR-138 mimic/miR-Con-
trol using Lipofectamine 2000. Firefly and Renilla lucif-
erase activities were measured using the Dual-Luciferase
Reporter Assay System (Promega). Results were
expressed as the firefly luciferase activity normalized to
Renilla luciferase activity.
Cell proliferation assay
Cell proliferation was determined by MTT assay. The cells
were suspended after transfection, and seeded into the 96-
well plates at a density of 1.5 × 103 cells/well. The cells
were allowed to grow for 24,48,72 and 96 h, and then
10 μl of MTT solution (0.5 mg/ml; Sigma, St.Louis, MO,
USA) was added to each well and incubated at 37 °C for
4 h. 150 μl of DMSO (Sigma) was added to dissolve the
formazan crystals. Cell viability was detected by measure-
ment of the absorbance at 570 nm using a microplate
reader (ELx800NB; BioTek Instruments, Inc., Winooski,
VT, USA).
Cell apoptosis assay
Forty-eight h after transfection, the cells were collected
and washed with PBS, and then resuspended in 500 μl of
binding buffer. 5 μl of Annexin V-FITC and 5 μl of propi-
dium iodide (PI) (Kaiji Biological Inc., Nanjing, Jiangsu,
China) were added to the samples, and incubated at room
temperature for 5 min in the dark. Positive cells were
analyzed by flow cytometry (FCM) (BD FACSAria; BD
Biosciences, Franklin Lakes, NJ, USA).
Transwell-Matrigel invasion assay
Transwell-Matrigel invasion assay was performed using
the Transwell inserts (Corning, New York, NY, USA)
coated with Matrigel (BD Biosciences, Franklin Lakes,
NJ, USA). The cells were seeded to the upper chambers
in serum-free medium at the density of 5 × 104 cells/ml
and in the amount of 2 ml/well. The lower chambers
were filled with DMEM containing 10 % FBS. After in-
cubation at 37 °C for 24 h, the non-invaded cells were
wiped with a cotton swab. The invaded cells were fixed
in 95 % ethanol and stained with hematoxylin. The num-
ber of invaded cells was counted under a microscope in
at least five fields.
Statistical analysis
Statistical analysis was performed on SPSS 19.0 statis-
tical software (SPSS, Inc., Chicago, IL, USA), and all the
data are presented as the means ± standard deviation. A
two-tailed Student’s t-test was used for comparison of
difference between 2 groups. P < 0.05 was considered to
indicate a statistically significant difference in the study.
Results
Mir-138 expression was downregulated in human
osteosarcoma tissues and cell lines
The expression level of miR-138 was quantified by real-
time quantitative reverse transcription PCR in primary
osteosarcoma tissues and osteosarcoma cell lines. Results
showed that compared with the adjacent normal tissues,
the expression level of miR-138 was significantly downreg-
ulated in human osteosarcoma tissues (Fig. 1a, P < 0.01).
Moreover, miR-138 expression was significantly lower in
metastatic osteosarcoma tissues than that in non-metastatic
tissues (Fig. 1b, P < 0.01). Compared with the normal bone
cell line hFOB, the expression levels of miR-138 were sig-
nificantly downregulated in osteosarcoma cell lines, includ-
ing MG-63, U2OS, SJSA-1, and Saos-2 (Fig. 1c, P < 0.01).
Mir-138 inhibited osteosarcoma cell proliferation and
invasion, and promoted cell apoptosis
We performed gain-of-function and loss-of-function ex-
periments to explore the role of miR-138 in human
osteosarcoma. To overexpress miR-138, miR-138 mimic
was transfected into the U2OS cells, which have low en-
dogenous miR-138 expression. In addition, miR-138 in-
hibitor was transfected into the MG-63 cells, which
exhibit high miR-138 expression, to knock down miR-
138 expression. The results from real-time quantitative
reverse transcription PCR analysis confirmed the ectopic
overexpression of miR-138 in U2OS cells and the deple-
tion of miR-138 expression in MG-63 cells (Figs. 2a and
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Fig 1 Mir-138 expression was downregulated in human osteosarcoma tissues and cell lines. a Fold change of miR-138 expression in human osteosarcoma
tissues and the adjacent normal tissues. #P< 0.01 compared with the normal. b Relative expression of miR-138 in the osteosarcoma tissues from the
patients with metastases and non-metastases. #P< 0.01 compared with the non-metastases tissues. c Fold change of miR-138 expression in human
osteosarcoma cell lines (MG-63, U2OS, SJSA-1, and SAOS-2) and the normal bone cell line (hFOB). #P< 0.01 compared with hFOB
Fig 2 Mir-138 mimic inhibited U2OS cell proliferation and invasion, and promoted cell apoptosis. a Fold change of miR-138 expression in U2OS
cells following transfection with the miR-138 mimic. b Cell viability c Cell apoptosis rate d Cell invasion of U2OS cells following transfection with
the miR-138 mimic. *P < 0.05 and #P < 0.01 compared with the miR-Ctrl
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3a, P < 0.01). 48 h after transfection, the cells were sub-
jected to cell proliferation, apoptosis and invasion assays.
Cell proliferation was determined by MTT assay, and the
results showed that miR-138 overexpression significantly
suppressed cell viability in U2OS cells, whereas miR-138
knockdown significantly enhanced cell viability in MG-63
cells (Figs. 2b and 3b, P < 0.05 for 48,72 and 96 h).
Flow cytometry indicated that U2OS cells with ectopic
overexpression of miR-138 showed a significant increase
in cell apoptosis rate compared with the control. On the
contrary, the knockdown of miR-138 in MG-63 cells re-
sulted in a significantly reduced cell apoptosis rate
(Figs. 2c and 3c, P < 0.01).
We further evaluated the effect of miR-138 on cell inva-
sion of osteosarcoma cells. Transwell-Matrigel invasion
assay demonstrated that the invasive ability of U2OS cells
transfected with the miR-138 mimic was much weaker
compared with the cells transfected with the miR-control
(miR-Ctrl); however, the invasive ability was significantly
enhanced in MG-63 cells following transfection with the
miR-138 inhibitor (Figs. 2d and 3d, P < 0.05).
DEC2 was a direct target of miR-138
DEC2 is predicted to be a potential target of miR-138 by
miRanda (http://www.microrna.org/). The predicted
interaction site of 7 bp of miR-138 and DEC2 3′UTR
was shown in Fig. 4a. To identify whether DEC2 is a dir-
ect target of miR-138, wild type and mutant DEC2 3′
UTR containing the putative target site of miR-138 were
cloned into reporter plasmids respectively, and were
transfected into the HEK293 cells along with the miR-
138 mimic, or the control miRNA. As validated by lucif-
erase reporter assay, the luciferase activity of wild type
DEC2-3′UTR was significantly suppressed in the cells
transfected with the miR-138 mimic compared with the
cells transfected with the miR-Ctrl (P < 0.01); however,
Fig 3 Mir-138 inhibitor promoted MG-63 cell proliferation and invasion, and inhibited cell apoptosis. a Fold change of miR-138 expression in MG-63
cells following transfection with the miR-138 inhibitor. b Cell viability c Cell apoptosis rate d Cell invasion of MG-63 cells following transfection with
the miR-138 inhibitor. *P < 0.05 and #P < 0.01 compared with the miR-Ctrl
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miR-138 mimic did not affect the luciferase activity of
mutant DEC2-3′UTR (Fig.4b).
Furthermore, we investigated the effect of miR-138 on
DEC2 expression in human osteosarcoma cell lines. We
found that miR-138 mimic significantly reduced DEC2 ex-
pression at the mRNA and protein level (0.60 ± 0.11
vs.0.32 ± 0.05, P < 0.05) in U2OS cells. In contrast, miR-138
inhibitor significantly increased the expression of DEC2
mRNA and protein (0.42 ± 0.05 vs.0.65 ± 0.08, P < 0.05) in
MG-63 cells (Fig. 4c,d).
DEC2 attenuated the effects of miR-138 on osteosarcoma
cells
To further illustrate whether miR-138 affects human osteo-
sarcoma cell proliferation, apoptosis and invasion through
DEC2, DEC2 overexpression plasmid was transfected into
the U2OS cells in the presence of miR-138 mimic,
whereas DEC2 siRNA was transfected into the MG-63
cells in the presence of miR-138 inhibitor. As shown in
Figs. 5a and 6a,the expression of DEC2 protein was signifi-
cantly increased in U2OS cells (0.30 ± 0.06 vs.0.70 ± 0.20,
P < 0.05) but decreased in MG-63 cells (0.68 ± 0.10
vs.0.37 ± 0.07, P < 0.05).
Forty-eight h after transfection, cell proliferation, apop-
tosis and invasion assays were performed. The increased
cell proliferation and invasion, and decreased cell apoptosis
in U2OS cells by miR-138 mimic transfection was attenu-
ated by the overexpression of DEC2 (proliferation, P < 0.05
for 48,72 and 96 h, Fig. 5b; apoptosis, P < 0.01, Fig. 5c;
invasion, P < 0.05, Fig. 5d). In MG-63 cells, the effect of
miR-138 inhibitor on cell proliferation, apoptosis and inva-
sion was also reversed by DEC2 suppression (proliferation,
P < 0.05 for 48,72 and 96 h, Fig. 6b; apoptosis, P < 0.01,
Fig. 6c; invasion, P < 0.05, Fig. 6d).
Fig 4 DEC2 was a direct target of miR-138. a The DEC2 3′UTR region containing the wild type or mutant binding site for miR-138. b The relative
luciferase activity of DEC2 wild type or mutant 3'UTR in HEK293 cells following transfection with the miR-138 mimic. c Fold change of DEC2
mRNA expression and relative DEC2 protein expression in U2OS cells following transfection with the miR-138 mimic. Lane 1, miR-Ctrl; lane 2, miR-138
mimic. d Fold change of DEC2 mRNA expression and relative DEC2 protein expression in MG-63 cells following transfection with the miR-138 inhibitor.
Lane 1, miR-Ctrl; lane 2, miR-138 inhibitor. *P < 0.05 and #P < 0.01 compared with the miR-Ctrl
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Discussion
MiR-138 has been proven to be a tumor suppressor gene
in various types of tumors. Long et al. reported that
downregulation of miR-138 in human colorectal cancer
tissues was associated with lymph node metastasis, dis-
tant metastasis, and predicted poor prognosis. Ectopic
expression of miR-138 can inhibit colorectal cancer mi-
gration and invasion in vitro and in vivo [12]. MiR-138
is also downregulated in HNSCC, and ectopically over-
expressed miR-138 in HNSCC suppressed cell invasion
and led to cell cycle arrest and apoptosis [17]. In ovarian
cancer, miR-138 can suppress cell invasion and metasta-
sis by targeting SRY-box 4 (SOX4) and hypoxia inducible
factor 1, alpha subunit (HIF-1α) [18]. A study by Poos
et al. reveals that miR-138 is significantly downregulated
in proliferative active osteosarcoma cell lines, and down-
regulation of miR-138 results in the upregulation of its
direct target genes which are involved in focal adhesion
[20]. In the present study, we found that miR-138 was
obviously downregulated in human osteosarcoma tissues
and cell lines. Moreover, miR-138 expression was signifi-
cantly lower in metastatic osteosarcoma tissues than that
in non-metastatic tissues. These findings suggested that
miR-138 may play important roles in the progression of
osteosarcoma. Subsequently, we performed the in vitro
gain-of-function and loss-of-function experiments to
elucidate the role of miR-138 in osteosarcoma. We
found that miR-138 inhibited cell proliferation and inva-
sion, and promoted cell apoptosis of human osteosar-
coma cells. Here, for the first time, we confirmed that
miR-138 acts as a tumor suppressor in human osterosar-
coma. Our report is consistent with the previous studies
showing the tumor suppressor role of miR-138 in other
types of tumors [12, 14, 17–19]. The further step of this
study need to investigate the association between miR-
138 expression and clinicopathological parameters of
osteosarcoma patients.
Several target genes of miR-138 have been identified and
verified in previous studies, such as vimentin, zinc finger e-
box binding homeobox 2 (ZEB2), GRK-Interacting Protein
1 (GIT1) and semaphorin-4c (SEMA4C) [19, 31, 32]. In
general, however, one miRNA has numerous target genes.
Among the candidate target genes of miR-138, we focused
on DEC2 because of its role as a regulator of cell prolifera-
tion, apoptosis, progression to malignancy, and carcinogen-
esis [22–26, 28, 29]. Furthermore, a recent study on the
association between DEC2 and osteosarcoma showed that
DEC2 contributes to the progression and metastasis of hu-
man osteosarcoma [30]. In the present study, we confirmed
DEC2 as a novel direct target of miR-138 by luciferase
Fig 5 DEC2 overexpression attenuated the effects of miR-138 mimic on osteosarcoma cells. a Relative DEC2 protein expression in U2OS cells following
transfection with the miR-138 mimic and DEC2 pcDNA3.1. Lane 1, miR-Ctrl + pcDNA3.1; lane 2, Mimic + pcDNA3.1; lane 3, Mimic + DEC2. b Cell viability
c Cell apoptosis rate d Cell invasion of U2OS cells following transfection with the miR-138 mimic and DEC2 pcDNA3.1.*P < 0.05 and #P < 0.01 compared
with the miR-Ctrl + pcDNA3.1; &P < 0.05 and @P < 0.01 compared with the Mimic + pcDNA3.1
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reporter assay. Furthermore, we demonstrated that miR-
138 suppresses DEC2 expression at the mRNA and protein
level.
The present study revealed that miR-138 exerts its ef-
fect on osteosarcoma cells, at least partially, by downreg-
ulating the expression of DEC2. DEC2 functions as a
transcriptional suppressor by binding to the E-box se-
quence in the promoter of various genes [33–35]. Some
studies showed that DEC2 physically interacts with and
promotes HIF-1α degradation, and suppresses the malig-
nant behaviour of human breast and pancreatic cancers
[23, 29]. Recently, a study by Hu et al. found that DEC2
facilitates HIF-1α stabilization and promotes HIF-1 acti-
vation in osteosarcoma, contributing to the progression
and metastasis of human osteosarcoma [30]. In this
study, we found DEC2 could reverse the inhibitory effect
of miR-138 on osteosarcoma progression, indicating that
DEC2 acts as an oncogene in osteosarcoma. This finding
was consistent with the report by Hu et al. [30]. Interest-
ingly, DEC2 have been demonstrated to suppress the
progression of breast, endometrial, pancreatic and oral
cancers [13, 21, 28, 29]; however, DEC2 was suggested
to be an oncogene in osteosarcoma. Therefore, we
speculate that the function of DEC2 in tumor cells ap-
pears to be cell type specific.
Conclusions
MiR-138 was downregulated in human osteosarcoma tis-
sues and cell lines. MiR-138 could inhibit osteosarcoma cell
proliferation and invasion, as well as promote cell apoptosis
through downregulating the expression of DEC2. This
study provided new insight into the mechanisms of osteo-
sarcoma carcinogenesis, and suggested miR-138/DEC2 as a
novel therapeutic target in osteosarcoma.
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